Answers are grounded in this paper and cite their sources.
Background: Risks of peri-conception exposure to botulinum toxin remain poorly characterized. Objective: To systematically evaluate the frequency of reported adverse maternal and fetal outcomes, including miscarriage, preterm labor, and congenital anomalies, in patients undergoing botulinum toxin injection in the peri-conception period compared to the general United States obstetric population. Methods: A PRISMA-guided systematic review identified studies (inception through November 7, 2025) reporting patient outcomes after botulinum toxin injection during the peri-conception period (3 months before and after conception). Reviews, editorials, and animal studies were excluded. Results: Of 586 articles, 10 met inclusion criteria. 80% of studies were case reports or series. Included studies comprised 136 women and 143 pregnancies (median age 33.5 years). Botulinum toxin was most commonly given for migraine (88%), dosed from 2.5 to 500 units. Five pregnancies (3%; n = 5; 95% CI: 1.5 − 8.0%) resulted in miscarriage. One case of preterm labor with fetal renal anomaly and one case of fetal growth restriction were reported. Conclusion: Peri-conception botulinum toxin exposure was not associated with increased adverse outcomes compared with population rates, though evidence is limited by small, heterogenous studies.
No takes yet. Share an insight, caveat, or question.
Azar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: